Compare AVAL & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AVAL | SRRK |
|---|---|---|
| Founded | 1994 | 2012 |
| Country | Colombia | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.5B |
| IPO Year | 2011 | 2018 |
| Metric | AVAL | SRRK |
|---|---|---|
| Price | $4.21 | $48.29 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | N/A | ★ $56.17 |
| AVG Volume (30 Days) | 251.2K | ★ 1.1M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.65% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $39.88 | N/A |
| Revenue Next Year | N/A | $534.24 |
| P/E Ratio | $12.86 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $27.07 |
| 52 Week High | $5.28 | $51.63 |
| Indicator | AVAL | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 45.73 | 51.79 |
| Support Level | $3.93 | $45.28 |
| Resistance Level | $4.29 | $51.34 |
| Average True Range (ATR) | 0.19 | 2.39 |
| MACD | -0.02 | -0.06 |
| Stochastic Oscillator | 41.67 | 50.94 |
Grupo Aval Acciones y Valores SA is a Colombian financial services company. Its segments include: Banking Services segment comprises Banking Services, fund management and trust businesses, storage companies and entities that manage low-value payment systems. Merchant Banking segment comprises Financial Sector (trust and brokerage), Gas and Energy Sector (includes natural gas and energy transportation and distribution businesses), Infrastructure Sector (includes road infrastructure projects, construction services, and operation and maintenance), Hotel Sector (includes hospitality services), Agribusiness Sector (includes palm oil, rubber and rice businesses). Pension and Severance Fund Management" segment comprise administrator of pension and severance funds; and Holding segment.
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.